Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest modafinil Stories

2014-01-13 08:28:21

Terms include $125 million upfront payment in cash plus a potential of up to $272 million in milestone payments DUBLIN, Jan. 13, 2014 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Aerial BioPharma, LLC (Aerial) today announced that the companies have signed a definitive agreement under which Jazz Pharmaceuticals has acquired rights to ADX-N05, a novel compound in clinical development for the treatment of excessive daytime sleepiness in patients with narcolepsy. Under the...

2013-10-09 16:23:49

PARIS, October 9, 2013 /PRNewswire/ -- Lancet Neurology, a prestigious journal in its domain, publishes in its last issue, an article entitled "Pitolisant versus placebo and modafinil in patients with narcolepsy: a double-blind randomised trial" authored by Y. Dauvilliers and others from the HARMONY I study group which proposes a novel treatment for this orphan disease. It is accompanied by a Commentary entitled "A need for new treatments in narcolepsy". Narcolepsy is a...

2013-09-19 12:29:00

Comprehensive patient survey documents delayed diagnosis and unmet medical needs for this devastating disease WORCESTER, Mass., Sept. 19, 2013 /PRNewswire-USNewswire/ -- On September 24, 2013, patients with narcolepsy and other stakeholders will gather at the Food & Drug Administration to provide direct input on drug development issues affecting nearly 200,000 Americans with narcolepsy. The meeting, fourth in a series of 20 mandated under a 2012 law, will be the first session dedicated...

2013-08-14 08:30:23

NEW YORK, Aug. 14, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released second quarter 2013 U.S. prescription sales data for the top 100 drugs. Since Q2 2012, Otuska's antipsychotic Abilify and AstraZeneca's acid reducer Nexium have held either the number one or two spot in top dollar sales. This quarter, both agents continue to maintain their stronghold; each posts close to $1.5 billion in sales. Humira, AbbVie's key tumor necrosis factor (TNF)...

2013-07-31 12:27:23

MUMBAI and BALTIMORE, July 31, 2013 /PRNewswire/ -- elsPharma Major Lupin Limited announced today that its U.S. subsidiary, Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Armodafinil Tablets, 50 mg, 100 mg, 150 mg, 200 mg and 250 mg strengths as well as another tentative approval for its Doxycycline Capsules, 40 mg (30 mg Immediate-release and 10 mg Delayed-release) from the United States Food and Drugs Administration (FDA). Lupin's...

2013-05-06 08:30:49

NEW YORK, May 6, 2013 /PRNewswire/ -- Drugs.com, the leading online clinical drug resource, today released first quarter 2013 U.S. prescription sales data for the top 100 drugs. (Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-a )(Photo: http://photos.prnewswire.com/prnh/20130506/PH07894-b ) The top five drugs have minor shifts in rank but exhibit positive growth for Q1 2013. Abilify, Otsuka's second generation antipsychotic, and Nexium, AstraZeneca's leading acid blocker,...

2012-08-10 02:22:50

PITTSBURGH, Aug. 10, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP,100 mg and 200 mg. This product is the generic version of Cephalon's Provigil® Tablets and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep...

2012-07-26 10:27:52

CHICAGO, July 26, 2012 /PRNewswire/ -- Provigil is being touted by some as the "secret to success" in the absence of a full night's sleep, but national sleep expert Dr. Craig Schwimmer warns the quick-fix solution could be detrimental to an already sleep-deprived American population. "I am very concerned that people have discovered yet another wonder pill they can pop when they get tired instead of figuring out how to change their lives in order to get the rest they need," said Dr....

2012-06-08 02:23:36

PITTSBURGH, June 8, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has resolved all disputes with Teva Pharmaceuticals USA, Inc. stemming from litigation brought by Mylan in federal court in the District of Columbia against the U.S. Food and Drug Administration (FDA) concerning Mylan's abbreviated new drug application (ANDA) for Modafinil Tablets, 100 mg and 200 mg. Modafinil Tablets are the generic version of Cephalon's...

2012-04-30 02:25:53

PITTSBURGH, April 30, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has entered into a settlement agreement with Teva that will resolve pending patent litigation related to Nuvigil® (Armodafinil Tablets, 50 mg, 150 mg, and 250 mg). The settlement allows Mylan to begin selling generic versions of 50 mg, 150 mg, and 250 mg Nuvigil under license beginning in June 2016, or earlier under certain circumstances. Pursuant to the agreement, pending litigation will be...